Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Review Article Volume 5 Issue 7

Clinical Pharmacy Interventions in Pediatric Intensive Care Unit: A Review

Annette Mariam Mathew and Juny Sebastian*

Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, India

*Corresponding Author: Juny Sebastian, Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, India.

Received: May 14, 2021; Published: June 29, 2021


Background: Clinical pharmacy is considered as the essential part of healthcare team in a hospital setting providing pharmaceutical care services to ensure the rational drug use. The outcome of clinical pharmacy intervention is the improvement of treatment effectiveness by providing alternative suggestions on the drug related problems and medication errors.

Methods: Extensive literature search was performed using various search engines. The identified articles were screened and segregated based on the inclusion criteria of studies on clinical pharmacy intervention in pediatric intensive care unit to prepare the review article.

Results: Clinical pharmacist’s involvement ensures in assessing, recommending and prevention of any event involving drug therapy that potentially interfere with health outcomes. Various studies shows that dose alteration and pharmacokinetic recommendation are the most common interventions made by clinical pharmacists. There are certain factors that can induce the occurrence of drug related problems (DRPs) including polypharmacy, disease comorbidities, and long hospitalization and transferred admissions. Studies found the incidence rate of 5.5 interventions per patient in pediatric intensive care units (PICU) that has significant impact on the health outcome. Specific consideration should be given to special population including pediatrics who are more likely to develop DRPs as pharmacodynamics and kinetic behaviors of drugs in this population differ from adults.

Conclusion: The identified contributing factors for DRPs in PICU are polypharmacy, long duration of hospital stay and comorbidities. As a part of the health care team, clinical pharmacist can review the treatment charts on daily basis to identify and suggest appropriate recommendations on identification of any DRPs or medication errors. These interventions can significantly improve the clinical and economical outcomes of patients admitted in PICUs.

Keywords: Clinical Pharmacy Intervention; Drug Related Problems; Medication Error; Pediatrics


  1. Dersch-Mills D. “Assessment Considerations in Pediatric Patients”. Inpatient Assessment in Clinical Pharmacy 2019 Springer, Cham 387-401.
  2. Maaskant JM., et al. “Medication audit and feedback by a clinical pharmacist decrease medication errors at the PICU: An interrupted time series analysis”. Health Science Reports3 (2018): e23.
  3. Conroy S., et al. “Survey of unlicensed and off label drug use in paediatric wards in European countries”. Bmj 7227 (2000): 79-82.
  4. Gorman RL., et al. “Prevention of medication errors in the pediatric inpatient setting”. Pediatrics 2 (2003): 431.
  5. Kaushal R., et al. “Medication errors and adverse drug events in pediatric inpatients”. JAMA 285 (2001): 2114‐2120.
  6. Ghaleb MA., et al. “The incidence and nature of prescribing and medication administration errors in paediatric inpatients”. Archives of Disease in Childhood2 (2010): 113-118.
  7. LaRochelle JM., et al. “Clinical pharmacy faculty interventions in a pediatric intensive care unit: an eight-month review”. The Journal of Pediatric Pharmacology and Therapeutics3 (2012): 263-269.
  8. Tripathi S., et al. “Impact of clinical pharmacist on the pediatric intensive care practice: an 11-year tertiary center experience”. The Journal of Pediatric Pharmacology and Therapeutics4 (2015): 290-298.
  9. Daniel L., et al. “An Investigation on Drug Related Problems in Pediatrics of a Tertiary Care, Private, Teaching Hospital at Coimbatore”. Journal of Clinical Case Reports and Trials 1 (2018): 1-7.
  10. Kearns GL., et al. “Developmental pharmacology—drug disposition, action, and therapy in infants and children”. New England Journal of Medicine12 (2003): 1157-1167.
  11. American Society of Hospital Pharmacists. “ASHP statement on pharmaceutical care”. American Journal of Health-System Pharmacy 50 (1993): 1720-1723.
  12. Rashed AN., et al. “Epidemiology and potential risk factors of drug‐related problems in Hong Kong paediatric wards”. British Journal of Clinical Pharmacology5 (2014): 873-879.
  13. Sutherland A., et al. “Exploring the human factors of prescribing errors in paediatric intensive care units”. Archives of Disease in Childhood6 (2019): 588-595.
  14. Bates DW., et al. “Incidence and preventability of adverse drug events in hospitalized adults”. Journal of General Internal Medicine6 (1993): 289-294.
  15. Okumura LM., et al. “Relation between safe use of medicines and clinical pharmacy services at pediatric intensive care units”. Revista Paulista de Pediatria 4 (2016): 397-402.
  16. Abrogoua DP., et al. “Assessment of a clinical pharmacy activity in a pediatric inpatient department in Cote d’Ivoire”. Journal of Basic and Clinical Pharmacy1 (2016): 15.
  17. Parthasarathi G., et al. “A Textbook of Clinical Pharmacy Practice Essential Concept and Skill”. (1 st edn) Oriental Longman Private Limited 193-245.
  18. Viana SD., et al. “Interventions of the clinical pharmacist in an Intermediate Care Unit for elderly patients”. Einstein (São Paulo)3 (2017): 283-288.
  19. Jafarian K., et al. “The responsibility of clinical pharmacists for the safety of medication use in hospitalized children: A Middle Eastern experience”. Journal of Research in Pharmacy Practice 2 (2019): 83.
  20. Malfara M., et al. “Impact of the clinical pharmacist interventions on prevention of pharmacotherapy related problems in the paediatric intensive care unit”. International Journal of Clinical Pharmacy 3 (2018): 513-519.


Citation: Annette Mariam Mathew and Juny Sebastian. “Clinical Pharmacy Interventions in Pediatric Intensive Care Unit: A Review". Acta Scientific Pharmaceutical Sciences 5.7 (2020): 164-170.


Copyright: © 2021 Annette Mariam Mathew and Juny Sebastian. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US